Prevymis
Payments companies reported to CMS as associated with Prevymis. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Prevymis, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Prevymis
These are the largest totals companies reported as associated with Prevymis. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Suphamai Bunnapradist | Los Angeles, CA | Nephrology (Internal Medicine) | $110,135.89 |
| Vinayak Rohan | Chicago, IL | Transplant Surgery | $76,808.51 |
| Juan Diaz | Altamonte Springs, FL | Infectious Disease | $32,600.64 |
| Cameron Wolfe | Durham, NC | Infectious Disease | $28,426.08 |
| Roy Chemaly | Houston, TX | Infectious Disease | $24,979.00 |
| Flavio Vincenti | San Francisco, CA | Internal Medicine | $24,116.14 |
| Genovefa Papanicolaou | New York, NY | Infectious Disease | $21,974.13 |
| Anup Patel | West Orange, NJ | $18,126.74 | |
| Yasir Qazi | Orange, CA | Nephrology (Internal Medicine) | $16,645.82 |
| Usama Gergis | Allentown, PA | Hematology & Oncology | $16,079.00 |
Prescribed Prevymis?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.